Project Description

Dermaref

ointment – Unguentum Dermaraef

international nonproprietary name

Not established

Ref

BP-0030

Pharmacotherapeutic group

Dermatotropic drug.

Composition of the preparation

1 g of the ointment contains 50 mg of bien.

Pharmacological action

A preparation for managing allergic dermatoses. The active agent of the ointment is BIEN – a complex of ethyl poly-unsaturated fatty acids having a hypoallergic and corrugating effects and stimulating reparative processes. The emulsion basis provides emollient and hydrating effects. The ointment removes the skin hyperemia and edema, normalizes its temperature, makes the skin folds thinner, restores the initial parameters of the dermal integument.

The dermaref clinical efficiency is higher than that of non steroid anti-inflammatory ointments.

When compared with similar local preparations (corticosteroids containing ointments) dermaref has a number of advantages: it does not exert allergic local and general reactions; it does not cause the skin athrophy, perioral dermatitis, acne, hirsutism.

Indications 

Atopic dermatitis, neurodermitis not atopic form, not exacerbated chronic eczema, allergic dermatitis, vulgar contact dermatitis.

special indication

Not established

special warning

Not established

Dosage and method of administration

A thin layer of the ointment is put on the skin areas impaired and is rubbed in carefully. Applications are made 2 times a day during 10 – 15 days. When the skin impairment is extended or in case of chronic dermatitis the ointment should be applied for 20 – 25 days, In case of allergic and vulgar contact dermatitis – for 6 – 10 days.

overdosage

No cases of dermaref ointment overdosing are described.

safety measures

No establisheed

Side effects

In rare cases light pruritus, burning, moderate hyperemia are possible. When side effects develop the ointment appliance should be stopped for 1 – 2 days; a histamine drug (suprastin, tavegil, fenkarol, gismanal, claritin), desensitivizing drugs (calcium gluconate per os 500 mg 3 times a day or 20% solution of sodium tiosulphate per os 1 tablespoon 3 times a day) should be prescribed. After the prutitus, burning in the foci of the impairment have stopped the dermaref local appliance may be continued.

Contraindications

Eczema at the exacerbation stage when the skin areas impaired become wet; skin syphilitic changes, tuberculosis of the skin, skin viral diseases, skin mycotic diseases.

Interactions with other medicinal preparations

No cases of a negative interaction with other medicines are described when dermaref ointment is applied on the background of treating by medicines included into the conventional schemes approved for managing allergic dermatoses.

The form of release

5% ointment. 15 g in glass pots or alluminium tubes. 0.5 kg in pots with necks for screwing.